MiR-155 controls follicular Treg cell-mediated humoral autoimmune intestinal injury by inhibiting CTLA-4 expression

High expression levels of miR-155 are involved in the pathogenesis of inflammatory bowel disease (IBD). We observed an increase in miR-155 in peripheral regulatory T (Treg) cells from IBD patients. Mice that specifically overexpress miR-155 in Foxp3+ Treg cells exhibit spontaneous autoimmunity and m...

Full description

Saved in:
Bibliographic Details
Published inInternational immunopharmacology Vol. 71; pp. 267 - 276
Main Authors Chao, Gao, Li, Xiaoli, Ji, Yahong, Zhu, Ying, Li, Na, Zhang, Nana, Feng, Zunyong, Niu, Min
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.06.2019
Elsevier BV
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:High expression levels of miR-155 are involved in the pathogenesis of inflammatory bowel disease (IBD). We observed an increase in miR-155 in peripheral regulatory T (Treg) cells from IBD patients. Mice that specifically overexpress miR-155 in Foxp3+ Treg cells exhibit spontaneous autoimmunity and more severe dextran sulfate sodium (DSS)-induced intestinal injury. MiR-155 overexpression can lead to a lack of follicular Treg (Tfr) cells and central Treg (cTreg), whereas DSS treatment further depletes the Tfr cells. Furthermore, miR-155 can target the expression of CTLA-4 in cTreg and Tfr, directly inhibiting Tfr cell production and promoting enhanced germinal center (GC) B cell activation and autoantibody overproduction. This outcome may be the cause of severe intestinal injury in patients with autoimmune IBD. •Increased levels of miR-155 are found in Treg cells of patients with IBD.•Rosa26miR-155Foxp3Cre mice exhibit autoimmune-induced and aggravated DSS-induced colitis.•miR-155 can be targeted to inhibit CTLA-4 expression in Tfr cells.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1567-5769
1878-1705
1878-1705
DOI:10.1016/j.intimp.2019.03.009